Cerebrospinal Fluid Biomarkers in Spinocerebellar Ataxia: A Pilot Study

Table 1

Patient demographics.

Patient demographics
	Control ()	MSA-C ()	SCA1 ()	SCA2 ()	SCA6 ()
Gender (F/M)	3/2	3/2	1/4	1/5	3/2
Age (mean ± SEM); range	50.8 ± 5.79; 34–70	55.4 ± 1.50; 50–59	52.0 ± 3.26; 43–61	54.0 ± 1.85; 49–59	53.4 ± 3.70; 45–66
Age at onset (mean ± SEM); range		47.2 ± 3.89; 32–53	41.2 ± 1.59; 38–47	32.7 ± 3.70; 18–44	37.6 ± 5.35; 25–55
Symptom duration, years; (mean ± SEM); range		8.2 ± 2.67; 3–18	10.8 ± 2.22; 4–15	23.6 ± 4.92; 11–40	15.8 ± 2.58; 11–25
SARA score (0–40); (mean ± SEM); range	0.375 ± 0.214; 0-1	20.7 ± 5.12; 8–39	11.1 ± 1.41; 6–14.5	9.7 ± 1.23; 6–13	15.9 ± 0.557; 14–17.5
Expanded CAG repeat size; (mean ± SEM); range			46 ± 1.58; 42–50	37.5 ± 0.34; 36–38	24 ± 1.29; 21–27

Data are shown as mean (standard error). SARA score is a validated rating scale for the severity of ataxia ranging 0–40.